Professional Media briefs

Share this article:
Fox P2 Media launched The Medical Roundtable, a peer-reviewed, subscriber-supported quarterly being distributed to over 5,000 US cardiologists. The first issue contains nine roundtable discussions spanning 68 pages and including 30 experts.

Wolters Kluwer made its Adis journal Drugs in R&D open access, with all content available online free of charge. The journal, for which access was formerly fee-based, features original research and reviews from all phases of clinical development.

Quadrant Healthcom named Toby Jane Hindin editor of The Female Patient. She joins the company from the health sciences division and the pharma/science division of Advanstar, where she was chief editor of Contemporary Pediatrics and editor in chief for Applied Clinical Trials. She reports to Margo Ullman, publisher.

Advanstar told Folio Magazine it will outsource production, resulting in the elimination of 100 jobs at its Duluth, MN location. With titles covering fashion and powersports as well as life sciences, the trade publisher is struggling to eliminate debt following its acquisition by private equity firm Veronis Suhler Stevenson in 2007.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Read the complete September 2014 Digital Edition

Read the complete September 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.

Medical marketing needs mainstream Mad Men

Medical marketing needs mainstream Mad Men

Agencies must generate emotional resonance with the target audience, not unlike Apple, Pepsi or Nike

Are discounts cutting out co-pays?

GSK's decision to cut Advair's price spurred some PBMs to put it back on formulary. Will drugmaker discounts diminish the need for loyalty programs? How can these programs stay relevant beyond giving co-pay assistance?